Nanoparticle Delivery of CRISPR/Cas9 for Genome Editing

The emerging clustered regularly interspaced short palindromic repeat (CRISPR)/CRISPR-associated system (Cas) gene-editing system represents a promising tool for genome manipulation. However, its low intracellular delivery efficiency severely compromises its use and potency for clinical applications...

Full description

Saved in:
Bibliographic Details
Published in:Frontiers in genetics Vol. 12; p. 673286
Main Authors: Duan, Li, Ouyang, Kan, Xu, Xiao, Xu, Limei, Wen, Caining, Zhou, Xiaoying, Qin, Zhuan, Xu, Zhiyi, Sun, Wei, Liang, Yujie
Format: Journal Article
Language:English
Published: Frontiers Media S.A 12.05.2021
Subjects:
CRISPR/Cas9
delivery
exosome
Genetics
modification
nanocarriers
ISSN:1664-8021, 1664-8021
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The emerging clustered regularly interspaced short palindromic repeat (CRISPR)/CRISPR-associated system (Cas) gene-editing system represents a promising tool for genome manipulation. However, its low intracellular delivery efficiency severely compromises its use and potency for clinical applications. Nanocarriers, such as liposomes, polymers, and inorganic nanoparticles, have shown great potential for gene delivery. The remarkable development of nanoparticles as non-viral carriers for the delivery of the CRISPR/Cas9 system has shown great promise for therapeutic applications. In this review, we briefly summarize the delivery components of the CRISPR/Cas9 system and report on the progress of nano-system development for CRISPR/Cas9 delivery. We also compare the advantages of various nano-delivery systems and their applications to deliver CRISPR/Cas9 for disease treatment. Nano-delivery systems can be modified to fulfill the tasks of targeting cells or tissues. We primarily emphasize the novel exosome-based CRISPR/Cas9 delivery system. Overall, we review the challenges, development trends, and application prospects of nanoparticle-based technology for CRISPR/Cas9 delivery.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Review-3
content type line 23
Reviewed by: Luan Wen, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences (CAS), China; Changzhi Zhao, Huazhong Agricultural University, China
Edited by: Linyuan Ma, University of Michigan, United States
This article was submitted to Genomic Assay Technology, a section of the journal Frontiers in Genetics
ISSN:1664-8021
1664-8021
DOI:10.3389/fgene.2021.673286